Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials

Executive Summary

AstraZeneca expects FDA's Oncologic Drugs Advisory Committee's Casodex review to focus on the apparent lower efficacy of the prostate cancer drug in U.S. trials compared to those outside the U.S
Advertisement

Related Content

Casodex Non-Metastatic Prostate Cancer Use Needs More Study – FDA Cmte.
Casodex Non-Metastatic Prostate Cancer Use Needs More Study – FDA Cmte.
Iressa Activity Not Likely Predicted By EGFR Expression Level – AstraZeneca
Iressa Activity Not Likely Predicted By EGFR Expression Level – AstraZeneca
GSK/Corixa Bexxar cmte. review?
Advertisement
UsernamePublicRestriction

Register

PS040752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel